MedTrace Logo

Mechanistic Inflammatory Sub-study Embedded Within the Albumin vs Balanced Crystalloid Trial

NCT04963569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2025-04-15

Study results available
· View outcomes & findings →

Summary

MIS-ABC Sepsis is a sub-study looking to understand how the immune response in patients with infection changes during the early stages of the illness, as well as after intravenous fluid treatment. Participants in the main trial will be given one of two types of fluid (Human Albumin Solution (HAS) and Balanced Crystalloid) via a drip when they present to the hospital with severe infection (sepsis). The main trial is assessing which fluid is better, and we are going to take three blood samples around the time people come to hospital to see what happens to their immune system as a result of the infection and fluid treatment. We hope our findings will explain why one fluid might be better than another. It may also give us an important information about whether we can predict which people might get sicker despite treatment.

Conditions

Sponsors & Collaborators

  • NHS Lothian

    collaborator OTHER_GOV

  • Royal College of Emergency Medicine

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Alasdair Gray, MD · University of Edinburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-06-08
Completion
2022-06-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04963569 on ClinicalTrials.gov